No connection

Search Results

ABUS vs OPK

ABUS
Arbutus Biopharma Corporation
BEARISH
Price
$4.53
Market Cap
$872.0M
Sector
Healthcare
AI Confidence
85%
OPK
OPKO Health, Inc.
BEARISH
Price
$1.18
Market Cap
$905.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABUS
--
OPK
--
Forward P/E
ABUS
-27.41
OPK
-3.58
P/B Ratio
ABUS
11.38
OPK
0.71
P/S Ratio
ABUS
61.92
OPK
1.49
EV/EBITDA
ABUS
-29.91
OPK
-7.29

Profitability

Gross Margin
ABUS
-79.23%
OPK
13.5%
Operating Margin
ABUS
-727.31%
OPK
-28.98%
Profit Margin
ABUS
-237.88%
OPK
-37.19%
ROE
ABUS
-38.52%
OPK
-17.14%
ROA
ABUS
-14.94%
OPK
-6.62%

Growth

Revenue Growth
ABUS
-33.2%
OPK
-19.2%
Earnings Growth
ABUS
--
OPK
--

Financial Health

Debt/Equity
ABUS
0.05
OPK
0.31
Current Ratio
ABUS
15.73
OPK
3.97
Quick Ratio
ABUS
15.52
OPK
3.21

Dividends

Dividend Yield
ABUS
--
OPK
--
Payout Ratio
ABUS
0.0%
OPK
0.0%

AI Verdict

ABUS BEARISH

ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.

Strengths
High current and quick ratios (15.73 and 15.52) indicate strong short-term liquidity
Low debt-to-equity ratio (0.05) suggests minimal leverage risk
Recent 1-year return of +34.4% shows strong price momentum despite fundamentals
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (up to -237.88%) and declining revenue (-33.20% YoY) indicate deteriorating business model
No operating cash flow or free cash flow data available, raising concerns about sustainability
OPK BEARISH

OPK exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical failures in profitability and operational efficiency. While the company maintains a strong liquidity position with a current ratio of 3.97 and low debt, these are offset by a -19.2% decline in year-over-year revenue and deeply negative profit margins. The stock is trading below its book value (P/B 0.71), but the persistent long-term price decay (-72.8% over 5 years) suggests a value trap rather than a bargain. Despite optimistic analyst price targets, the deterministic data points to a company in structural decline.

Strengths
Strong short-term liquidity (Current Ratio 3.97)
Low leverage (Debt/Equity 0.31)
Trading at a discount to book value (P/B 0.71)
Risks
Severe operational weakness (Piotroski F-Score 1/9)
Significant revenue contraction (-19.2% YoY)
Deeply negative profit margins (-37.19%)

Compare Another Pair

ABUS vs OPK: Head-to-Head Comparison

This page compares Arbutus Biopharma Corporation (ABUS) and OPKO Health, Inc. (OPK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile